LabCorp licenses NASH test for clinical research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/omgimages)
(Image: Getty/omgimages)

Related tags: Clinical research, CRO, regulatory approval, Clinical development, facility

LabCorp’s Covance has signed an agreement which it will use Genfit’s diagnostic test to identify and characterize patients.

Genfit has developed a non-invasive test for non-alcoholic steatohepatitis (NASH) using its blood-based biomarker test.

Covance, the drug development business of LabCorp, will validate the test’s use for identification and characterization of patients, and to generate biological insights on the pathogenesis of NASH. 

NIS4, Genfit’s test, used samples from 687 patients from two different cohorts to discover and internally validate the test, a spokesperson from Genfit told us. Through the agreement, the companies may be positioned to expand access of NIS4 to clinical research.

Currently, there are no extensively validated non-invasive diagnostic tests for NASH that address the evolving disease and therapeutic implications.

Through the partnership, LabCorp will distribute the test to clinical research facilities. Genfit will aim to release the test as a laboratory developed test (LDT) as early as 2019 for clinical research.

The Genfit spokesperson told us the goal of the partnership is “to provide an approved solution for routine clinical care that could be performed by any specialist.”

Genfit said it aims to submit a diagnostic test package for regulatory approval by 2020 in the US and Europe.

“Our ambition at this stage is much broader, with a solution designed to help all NASH patients, including those who will be identified as not needing drug therapy,”​ the spokesperson explained. “So not only will the diagnostic kit potentially improve the patient journey, help providers in identifying and managing patients, but we believe it will also allow researchers to collect essential data on NASH, and hopefully improve the understanding of its complex mechanisms.”

Financial terms for the agreement were not disclosed

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

Related suppliers

Follow us

Products

View more

Webinars